Brief: Cocrystal Pharma Gets FDA Nod for Study of CDI-988, First Oral Antiviral Targeting Norovirus
08/09/2025 13:01
Sept 8 (Reuters) - Cocrystal Pharma Inc COCP.O: COCRYSTAL PHARMA RECEIVES FDA IND CLEARANCE FOR CHALLENGE STUDY OF ORAL BROAD-SPECTRUM PROTEASE INHIBITOR CDI-988, A POTENTIAL FIRST ANTIVIRAL FOR NOROVIRUS PREVENTION AND TREATMENT COCRYSTAL PHARMA INC - PHASE 1B STUDY EXPECTED TO START BY YEAR-END 2025 Source text: ID:nGNX7QvRMN Further company coverage: COCP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway